TABLE 30Incremental costs, QALYs and ICERs for PhVIT +AAI + HDA for the ‘High Risk of Sting Patients’ subgroup

AAI + HDAAvoidance advice only
Incremental cost−£1,057,682−£1,293,972
Incremental QALYs5.9115.06
Cost per QALY (ICER)−£179,020−£85,903

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy
A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy.
Health Technology Assessment, No. 16.12.
Hockenhull J, Elremeli M, Cherry MG, et al.
Southampton (UK): NIHR Journals Library; 2012 Mar.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.